First CRISPR clinical trial gets green light from US panel

@article{Reardon2016FirstCC,
  title={First CRISPR clinical trial gets green light from US panel},
  author={Sara Reardon},
  journal={Nature},
  year={2016}
}
The technique's first test in people could begin as early as the end of the year. 

Safety and Security Risks of CRISPR/Cas9

This case study looks into recent developments with regard to the CRISPR/Cas9 and other novel genome editing technologies that are becoming widely available thanks to their low costs and modest

Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic

Some of the major challenges for clinicians, regulators, and human research ethics committees in the clinical translation of CRISPR-mediated somatic cell therapy are identified.

Multifunctional CRISPR/Cas9 with engineered immunosilenced human T cell epitopes

This proof-of-principle study demonstrates that Cas9 protein can be modified to eliminate immunodominant epitopes through targeted mutation while preserving its function and specificity.

First-in-human Phase 1 CRISPR Gene Editing Cancer Trials:Are We Ready?

The proposed first-in-human Phase 1 CRISPR gene editing cancer trial in the United States cannot satisfy the ethical requirement of scientific validity because the supporting pre-clinical evidence used to inform trial design is deficient.

The clinical potential of gene editing as a tool to engineer cell-based therapeutics

The clinical application of ex vivo gene edited cell therapies first began a decade ago with zinc finger nuclease editing of autologous CD4 + T-cells, and there is growing interest in allogeneic and off-the-shelf approaches and multiplex editing strategies are increasingly employed.

Gene editing for advanced therapies: Governance, policy and society

Gene editing aims to modify the genetic sequence at a precise genomic location. Recent breakthroughs in gene editing techniques such as the clustered regularly interspaced short palindromic repeats

Approaches to Reduce CRISPR Off-Target Effects for Safer Genome Editing

Several techniques for pursuing more precise genome editing through CRISPR are reviewed and biosafety professionals are provided with current information regarding the state ofCRISPR technology and examples of publicly available resources for predicting the likelihood of off-target effects.

The Future of CRISPR Applications in the Lab, the Clinic and Society.

In the case of human health, CRISPR operates as both a tool of discovery and a solution to fundamental problems behind disease and undesirable mutations.
...